COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Shareholder Update: Review of 2023 and Outlook for 2024
Aztec Minerals Corp. (TSXV:AZT)(OTCQB:AZZTF) provides a review of 2023 and its outlook for 2024, highlighting advancements in its projects and corporate side, including the Tombstone Project's drilling program and the Cervantes Project's exploration program. The company appointed a new CFO, raised $2.6 million in equity financings, and is well positioned to create substantial shareholder value in 2024. The press release also provides details on the 2023 highlights and the 2024 outlook for Aztec Minerals Corp. -
COMMUNIQUÉ DE PRESSE
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
Zomedica Corp. announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients without sedation. The article describes the use of a novel shockwave trode, reinforcing current clinical evidence on the effectiveness of electro-hydraulic shock wave therapy for various indications. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available on Frontiers in Veterinary Science. In addition, CSU is evaluating PulseVet therapy for slowing the progression of canine osteoarthritis, with expected results later in 2024. The ability to treat patients without sedation using X-Trode is seen as a major advancement. Zomedica's Vice President of Clinical and Veterinary Affairs, Adrian Lock, expressed excitement for the upcoming study to further validate the therapy's efficacy. The company's CEO, Larry Heaton, believes the publication will accelerate the acceptance of shock wave therapy for small animal patients. PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells, promoting healing growth factors. Zomedica's commitment to advancing veterinary care is evident through ongoing clinical studies and product innovations. The company's mission to address the unmet needs of clinical veterinarians underscores its dedication to animal welfare and better veterinary practice. For more information, readers can visit Zomedica's website. -
COMMUNIQUÉ DE PRESSE
NanoViricides to Present at the Biotech Showcase in San Fransisco
NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections. -
COMMUNIQUÉ DE PRESSE
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Tryp Therapeutics Inc. is pleased to announce the dosing of the first patient in a Phase 2a clinical trial for fibromyalgia using their proprietary IV-infused psilocin, TRP-8802. With positive results, the company aims to further develop TRP-8803 to provide relief to millions of patients suffering from chronic pain. Learn more about Tryp's innovative therapies at www.tryptherapeutics.com. -
COMMUNIQUÉ RÉGLEMENTÉ
Edenred - Disclosure of Share Capital and Voting Rights as of December 31, 2023
This press release discloses the share capital and voting rights of Edenred as of December 31, 2023, in accordance with the French Commercial Code and the General Regulations of the Autorité des marchés financiers. The total shares outstanding, potential voting rights, and exercisable voting rights are provided, excluding rights attached to shares held in treasury. More information can be found on edenred.com, Investors/Shareholders section then Regulated Information. -
COMMUNIQUÉ RÉGLEMENTÉ
Edenred - Déclaration du nombre d'actions et de droits de vote au 31 décembre 2023
Edenred déclare le nombre d'actions et de droits de vote conformément à la réglementation en vigueur. Toute l’information est disponible sur le site web edenred.com, rubrique Investisseurs / Actionnaires -
COMMUNIQUÉ RÉGLEMENTÉ
LNA Santé : Répartition de capital et des droits de vote attachés aux actions au 31/12/2023
Déclaration de répartition de capital et droits de vote pour LNA Santé au 31/12/2023 par Société Générale conformément à l'article 223-16 du règlement général de l'Autorité des Marchés Financiers -
-
COMMUNIQUÉ DE PRESSE
Canadian Overseas Petroleum Ltd Announces Conversion of Bond Payments
Canadian Overseas Petroleum Limited announces the issuance of 305,598,679 common shares for the settlement of Conversion Payment amounts. The Company now has a total of 1,344,370,498 common shares issued and outstanding. Shareholders may use this figure for the necessary calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Common Shares will be admitted to the FCA's Official List and to trading on the London Stock Exchange's main market for listed securities within the next twelve months. For further information, please refer to the contact details provided in the press release.
